Remyelination in Multiple Sclerosis: Where Do We Stand?

In this roundtable discussion, Ari Green, MD, and Paul Tesar, PhD, delve into the current landscape of remyelination in multiple sclerosis (MS), offering expert perspectives on one of the field’s most pressing therapeutic frontiers. The panel explores how our understanding of remyelination has evolved, the tools used to measure it in human studies, and the challenges of translating early scientific success into clinical progress. The conversation also touches on the impact of aging and disease duration on remyelination potential, highlights novel agents in clinical trials, and debates whether remyelination should be pursued as a standalone strategy or in combination with immunomodulatory therapy. Looking ahead, the experts outline the innovations in imaging, trial design, and therapeutic development that could help close the gap between discovery and clinical application.